Newer Agents in the Treatment of Multiple Sclerosis
Neurologist 19:104-117, Pawate, S. & Bagnato F., 2015
Multiple Sclerosis Therapeutics: Unexpected Outcomes Clouding Undisputed Successes
Neurol 72:1008-1015, Wiendl,H. &Hohlfeld,R., 2009
Human Natural Autoantibodies in the Treatment of Neurologic Disease
Neurol 72:1269-1276, Rodriguez,M.,et al, 2009
Effect of Laquinimod on MRI-Monitored Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IIb Study
Lancet 371:2085-2092,2059, Comi,G.,etc., 2008
Monoclonal Antibody Therapies and Neurologic Disorders
Arch Neurol 65:1162-1165, Novack,J.C.,et al., 2008
Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
NEJM 359:1786-1801,1838, The CAMMS223 Trial Investigators, 2008
Natalizumab Plus Interferon Beta -1a for Relapsing Multiple Sclerosis
NEJM 354:911-923,965, Rudick,R.A.,et al, 2006
Multiple Sclerosis: New Insights and Trends
AJNR 27:954-957, Inglese,M., 2006
Multiple Sclerosis: The Role of MR Imaging
AJNR 27:1165-1176, Ge,Y., 2006
Emerging Monoclonal Antibody Therapies for Multiple Sclerosis
Neurologist 12:171-178, Cree,B., 2006
Recent Developments in Neurology
BMJ 324:656-660, Wiebe,S.,&Nicolle,M.W., 2002
Recent Advances, Neurology
BMJ 319:362-366, Larner,A.J.&Farmer,S.F., 1999
Imaging the Brain, Part 1 & 2
NEJM 338:812-820, 889-8961998., Gilman,S., 1998
Chromosome 19 Single-Locus & Multilocus Haplotype Assoc with MS, Evid of New Suscept Locus in Caucasian & Chinese Pts
JAMA 278:1256-1262, 12821997., Barcellos,L.F.,et al, 1997